Publication Name	World Journal of Diabetes
Manuscript ID	3992
Country	Switzerland

Received	2013-06-06 20:23
Peer-Review Started	2013-06-07 11:21
First Decision by Editorial Office Director
Return for Revision	2013-07-25 12:03
Revised	2013-08-12 20:45
Publication Fee Transferred
Second Decision by Editor	2013-10-17 13:18
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-10-18 06:59
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-06 09:24
Publish the Manuscript Online	2013-12-20 16:49

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Autobiography
Article Title	Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan
Manuscript Source	Invited Manuscript
All Author List	Abhijit Shete, Aheson Shaikh, K Javeed Nayeem, Lily Rodrigues, Mohamed Sheikamunadeen Sadiq Ali, Parag Shah, Rajiv Khanna, Sarfaraj Majid, Sabeer A Rasheed, Shehla Shaikh and Tawfiqur Rahman
Funding Agency and Grant Number	Funding Agency Grant Number Novartis Healthcare Private Limited, India
Corresponding Author	Dr. Abhijit Shete, MD, Medical Department, Novartis Pharma AG, Core Technology Area, CH-4002, Basel, Switzerland. abhijit.shete@novartis.com
Key Words	Dipeptidyl-peptidase 4 inhibitors; Fasting hypoglycemia; Sulfonylurea; Type 2 diabetes mellitus; Vildagliptin
Core Tip	Management of glycemic control in diabetes patients fasting during Ramadan has been recognized as a critically important health challenge worldwide. India has the world’s second largest diabetes population and caters large Muslim community; however, there is limited data available exploring the effect of treatments in these fasting diabetes patients. This non-interventional, multicenter, double-arm study compared the effect of vildagliptin with sulfonylureas on hypoglycemic events, HbA1c, blood glucose levels, and response rate in 97 fasting diabetic patients during Ramadan in real-world setting. Vildagliptin appears to be an attractive treatment option for diabetes patients fasting during Ramadan.
Publish Date	2013-12-20 16:49
Citation	Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S, Rahman T. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4(6): 358-364 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i6/358.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i6.358
URL	http://www.wjgnet.com/1948-9358/full/v4/i6/358.htm
DOI	http://dx.doi.org/10.4239/wjd.v4.i6.358

Full Article (PDF)	WJD-4-358.pdf
Full Article (Word)	WJD-4-358.doc
Manuscript File	3992-Review.docx
Answering Reviewers	3992-Answering reviewers.pdf
Copyright License Agreement	3992-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics Committee Approval Letter_Vildagliptin Versus Sulfonylurea in Indian Muslim Diabetes Patients Fasting During Ramadan.pdf
Peer-review Report	3992-Peer reviewer(s).pdf
Scientific Editor Work List	3992-Scientific editor work list.doc